Antiplatelet therapy is the cornerstone of secondary prevention of Stroke and TIA. But in contrast to acute coronary syndrome where patients get one year of aspirin plus clopidogrel, is there evidence of benefit for combination therapy after stroke/TIA? This article helps answer this question and informs our current practice.
Some questions to consider while reviewing this article:
- Will this trial influence how you currently treat patients with CVA?
- How might the inclusion and exclusion criteria have influenced the results of the study?
- What criticisms do you have regarding the study design? Does the design make sense?
No Url Found